Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

Exclusion Criteria

• •Infants born prematurely (delivery before 37 weeks gestation) or with low birth weight (\<2500g) at 2 months (60-89 days) or 3 months (90-119 days) of age;
• •Infants aged 2 months (60-89 days) or 3 months (90-119 days) with history of abnormal labor, asphyxia requiring resuscitation, or neurological impairment;
• •Severe congenital malformations or developmental disorders, genetic defects, or severe malnutrition;
• •History of severe adverse reactions or anaphylaxis to vaccines or vaccine components, such as urticaria, dyspnea, angioedema;
• •History of epilepsy, convulsions, seizures, cerebral palsy, psychiatric disorders, or family history thereof; or history of progressive neurological diseases (e.g., Guillain-Barré syndrome, brachial plexus neuritis);
• •Diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis (JRA), or other autoimmune diseases;
• •Acute illness (e.g., fever ≥38.5°C, diarrhea) or acute exacerbation of chronic disease within 3 days prior to receiving the investigational product;
• •Known or suspected severe chronic diseases (including: severe respiratory disease, severe cardiovascular disease, liver/kidney disease, severe dermatology conditions, malignancies, etc.);
• •Current anal abscess or severe eczema;
• •Clinically diagnosed coagulation disorders (e.g., factor deficiency, bleeding disorders, platelet abnormalities) or significant bruising/coagulation impairment;
• •Asplenia, functional asplenia, or splenectomy due to any cause;
• •Continuous treatment with immunosuppressants, immunomodulators, or cytotoxic agents (exceeding 10 days) within the past 6 months; inhaled or topical steroids are permitted;
• •Receipt of blood products or immunoglobulins (excluding hepatitis B immunoglobulin) within the past 3 months;
• •Received an injectable live attenuated vaccine within 14 days, or any other vaccine within 7 days;
• •Taken antipyretic analgesics or antiallergic medications within 3 days;
• •Fever present prior to vaccination, with axillary temperature ≥37.3°C (99.3°F);
• •Plans to participate in or is currently participating in any other drug/vaccine clinical trial;
• •Any other factors deemed by the investigator to make the subject unsuitable for participation in the clinical trial.
• •Infants aged 2 months (60-89 days) who have received vaccines containing meningococcal, DTP, or Haemophilus influenzae type b components;
• •Infants aged 3 months (90-119 days) who have received a vaccine containing meningococcal components;
• •Individuals aged 18-24 months who have received vaccines containing meningococcal or Haemophilus influenzae type b components within the past six months;
• •Individuals aged 18-24 months with abnormal pre-vaccination blood count or urinalysis results deemed clinically significant by the investigator;
• •Children aged 6 years who, prior to vaccination, exhibit abnormal results in relevant indicators of complete blood count, blood biochemistry, coagulation function, or urinalysis, and are deemed clinically significant by the investigator;
• •Individuals with a history of any of the following diseases: meningococcal meningitis, Haemophilus influenzae type b disease, pertussis, diphtheria, or tetanus.
• •History of vaccination with any meningococcal-containing vaccine;
• •Occurrence of a serious adverse event related to vaccination following the previous dose;
• •Vaccine-related Grade 3 or higher allergic reaction following the previous dose;
• •Any other factors deemed by the investigator to make the subject unsuitable for continued participation in the clinical trial.